Philippe G. Prokocimer
Nessuna posizione attualmente
Storia della carriera di Philippe G. Prokocimer
Precedenti posizioni note di Philippe G. Prokocimer
Società | Posizione | Inizio | Fine |
---|---|---|---|
Johnson & Johnson Pharmaceutical Research & Development LLC
Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Direttore Tecnico/Scientifico/R&S | 01/01/2007 | 01/01/2007 |
Maxim Pharmaceuticals, Inc. | Direttore Tecnico/Scientifico/R&S | 01/01/2003 | 01/01/2003 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Direttore Tecnico/Scientifico/R&S | 01/01/2001 | 01/01/2001 |
ABBOTT LABORATORIES | Direttore Tecnico/Scientifico/R&S | 01/01/1994 | 01/01/1994 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | 11/07/2007 | - |
Formazione di Philippe G. Prokocimer
Centre Hospitalier Universitaire Pitie-Salpetriere | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Francia | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 5 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Aziende private | 4 |
---|---|
Maxim Pharmaceuticals, Inc. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Johnson & Johnson Pharmaceutical Research & Development LLC
Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Commercial Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |